135 related articles for article (PubMed ID: 27311884)
1. Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation.
Fiala MA; Park S; Slade M; DiPersio JF; Stockerl-Goldstein KE
Transfusion; 2016 Sep; 56(9):2331-5. PubMed ID: 27311884
[TBL] [Abstract][Full Text] [Related]
2. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
7. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
9. The use of hematocrit level for predicting the efficiency of peripheral blood CD34(+) cell collection after G-CSF Mobilization in Healthy Donors.
Pornprasertsud N; Niparuck P; Kidkarn R; Puavilai T; Sirachainan N; Pakakasama S; Hongeng S; Jootar S; Ungkanont A
J Clin Apher; 2015 Dec; 30(6):329-34. PubMed ID: 25663039
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.
Anderlini P; Donato M; Chan KW; Huh YO; Gee AP; Lauppe MJ; Champlin RE; Körbling M
Transfusion; 1999 Jun; 39(6):555-60. PubMed ID: 10378833
[TBL] [Abstract][Full Text] [Related]
11. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF.
de Fabritiis P; Iori AP; Mengarelli A; Gozzer M; Ferrazza G; De Propris MS; Romano A; Arcese W
Transfusion; 2001 Feb; 41(2):190-5. PubMed ID: 11239221
[TBL] [Abstract][Full Text] [Related]
12. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
14. Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor.
Chen J; Burns KM; Babic A; Carrum G; Kennedy M; Segura FJ; Garcia S; Potts S; Leveque C
Transfusion; 2014 Jan; 54(1):203-10. PubMed ID: 23763340
[TBL] [Abstract][Full Text] [Related]
15. Effect of G-CSF on peripheral blood progenitor cell mobilization and collection from healthy donors.
Chaisiripoomkere W; Jootar S; Ungkanont A
Asian Pac J Allergy Immunol; 2001 Sep; 19(3):183-90. PubMed ID: 11826913
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.
Panch SR; Yau YY; Fitzhugh CD; Hsieh MM; Tisdale JF; Leitman SF
Transfusion; 2016 May; 56(5):1058-65. PubMed ID: 27167356
[TBL] [Abstract][Full Text] [Related]
17. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
[TBL] [Abstract][Full Text] [Related]
19. Predictive parameters for granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization.
Okano A; Ashihara E; Shimazaki C; Uchiyama H; Inaba T; Taniguchi K; Maekawa T; Taniwaki M
J Clin Apher; 2008; 23(6):171-7. PubMed ID: 18988229
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
